Cargando…

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

PURPOSE: The most common cause of death in advanced/metastatic hepatocellular carcinoma (HCC) is liver failure due to tumor progression. While retrospective studies and meta-analyses of systemic therapy combined with liver-directed therapy have been performed, prospective studies of safety/efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaseb, Ahmed Omar, Kappadath, S Cheenu, Lee, Sunyoung S, Raghav, Kanwal Pratap, Mohamed, Yehia I, Xiao, Lianchun, Morris, Jeffrey S, Ohaji, Chimela, Avritscher, Rony, Odisio, Bruno C, Kuban, Joshua, Abdelsalam, Mohamed E, Chasen, Beth, Elsayes, Khaled M, Elbanan, Mohamed, Wolff, Robert A, Yao, James C, Mahvash, Armeen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437411/ https://www.ncbi.nlm.nih.gov/pubmed/34527608 http://dx.doi.org/10.2147/JHC.S318865

Ejemplares similares

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
por: Teyateeti, Ajalaya, et al.
Publicado: (2021)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Blood flow diversion using the microvascular plug to avoid non target delivery of radioactive microspheres
por: Abdelsalam, Mohamed E., et al.
Publicado: (2020)

Temporary Balloon Occlusion of the Common Hepatic Artery for Yttrium-90 Glass Microspheres Administration in a Patient with Hepatocellular Cancer and Renal Insufficiency
por: Smith, Justin, et al.
Publicado: (2013)

Temporary Reversal of Hepatoenteric Collaterals during (90)Y Radioembolization Planning and Administration
por: Habibollahi, Peiman, et al.
Publicado: (2022)

Minimally invasive image-guided therapies for hepatocellular carcinoma
por: Abdelsalam, Mohamed E, et al.
Publicado: (2016)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy
por: Mikell, Justin K, et al.
Publicado: (2015)

A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of (90)Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study
por: Mahvash, Armeen, et al.
Publicado: (2022)

Factors modulating (99m)Tc‐MAA planar lung dosimetry for (90)Y radioembolization
por: Lopez, Benjamin P., et al.
Publicado: (2022)

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma
por: Niekamp, Andrew, et al.
Publicado: (2018)

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy
por: Hosseini Shabanan, Sedighe, et al.
Publicado: (2022)

Hepatic Abscess following Yttrium-90 Radioembolization in Patients with Surgical Bilioenteric Anastomosis or Compromised Sphincter of Oddi: A Tertiary Cancer Center Experience
por: Agahi, Kevin N., et al.
Publicado: (2022)

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients
por: Mohamed, Yehia I., et al.
Publicado: (2022)

Effects of voxel size and iterative reconstruction parameters on the spatial resolution of [Formula: see text] SPECT/CT
por: Kappadath, S. Cheenu
Publicado: (2011)

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Mohamed, Yehia I., et al.
Publicado: (2021)

A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis
por: Taiji, Ryosuke, et al.
Publicado: (2023)

Characterization of the energy response and backscatter contribution for two electronic personal dosimeter models
por: Meier, Joseph, et al.
Publicado: (2015)

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma
por: Kaseb, Ahmed O., et al.
Publicado: (2022)

International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres
por: Levillain, Hugo, et al.
Publicado: (2021)

Single-Compartment Dose Prescriptions for Ablative (90)Y-Radioembolization Segmentectomy
por: Kappadath, Srinivas Cheenu, et al.
Publicado: (2023)

Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma
por: Lam, Marnix, et al.
Publicado: (2023)

Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model
por: Henry, E. Courtney, et al.
Publicado: (2022)

Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation
por: Moawad, Ahmed W., et al.
Publicado: (2023)

Observed intercamera variability in clinically relevant performance characteristics for Siemens Symbia gamma cameras
por: Kappadath, S. Cheenu, et al.
Publicado: (2006)

Correction: Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model
por: Henry, E. Courtney, et al.
Publicado: (2023)

A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis
por: Kairemo, Kalevi, et al.
Publicado: (2020)

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
por: Awiwi, Muhammad O, et al.
Publicado: (2022)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review
por: El Kassas, Mohamed, et al.
Publicado: (2019)

Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group
por: Salem, Riad, et al.
Publicado: (2022)

Understanding Idiopathic Spinal Cord Herniation – A Comprehensive Review of Imaging and Literature
por: Sharma, Pranav, et al.
Publicado: (2019)

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
por: Gok Yavuz, Betul, et al.
Publicado: (2021)

Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study
por: Lacin, Sahin, et al.
Publicado: (2020)

Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial
por: Vilgrain, Valérie, et al.
Publicado: (2014)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Reassessment of the lung dose limits for radioembolization
por: Kappadath, S. Cheenu, et al.
Publicado: (2021)

A Retrospective Comparative Study of Sodium Fluoride Na(18)F-PET/CT and (68)Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis
por: Kairemo, Kalevi, et al.
Publicado: (2022)

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
por: Taha, Amna Mohamed, et al.
Publicado: (2022)

Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
por: Braat, A. J. A. T., et al.
Publicado: (2019)

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma
por: Chamseddine, Shadi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iap92j1dmu1v40qtdqu8330as6